A date for your diary: the next course an "Update on Pharmacoeconomics in the Irish Healthcare Setting" will take place on 15th & 16th May 2019 in Dublin Castle. Programme to follow.
The NCPE recommends that avelumab (Bavencio®) for the treatment of metastatic Merkel Cell Carcinoma not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.
The NCPE recommends that ocrelizumab (Ocrevus®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.